Just four days after Germantown's Intrexon Corp. made public plans to rebrand as Precigen, its subsidiary by the same name has secured a coveted regulatory designation for its blood cancer treatment. bizjournals.com/washington/n…
Great news from our partners at #Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for #oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our #ActoBiotics® platform and licensed to Oragenics. More: actobio.com
At #BIOInvestorForum? Don’t miss #ActoBio Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform today Wednesday October 23 @ 9:15 AM PT. Read more: actobio.com or follow us on LinkedIn or Twitter @ActobioT#bif19#biotech